SIM0723

SIM0723 is an investigational drug candidate currently in early-stage development by Simcere Pharmaceutical (Jiangsu Xiansheng). The drug appears in the company's research pipeline across two distinct therapeutic areas: autoimmune diseases and anti-infectives. In the autoimmune context, it is associated with the target **CD122** (Interleukin-2 receptor subunit beta), which is a critical component of the IL-2 and IL-15 receptor complexes involved in the regulation of T-cell and Natural Killer (NK) cell activity. In the anti-infective context, the drug is linked to the inhibition of **RNA-directed RNA polymerase (RdRp)**, an essential enzyme for the replication of various RNA viruses. Due to the disparate nature of these targets and the early stage of the program, the dual listing of the SIM0723 code may reflect a platform-based approach or potential transcription/OCR errors in pipeline documentation (possibly misidentifying related assets such as SIM0423). The candidate is currently in the preclinical or early clinical phase of development.

Other names

CD1/2RUP4/5